BioXgen Unveils Cardiac Patch, Opens Investment Offering

The company's FDA-bound device aims to prevent a common open-heart surgery complication.

Apr. 17, 2026 at 7:00pm by

Got story updates? Submit your updates here. ›

A close-up, photorealistic studio photograph of a polished, geometric cardiac patch device made of premium materials, arranged elegantly on a clean, monochromatic background with dramatic lighting and deep shadows, conceptually representing cardiac health, surgical innovation, and medical technology.BioXgen's innovative cardiac patch device, designed to prevent a common complication of open-heart surgery, takes center stage in this high-end studio still life.San Francisco Today

BioXgen, a medical device startup, has announced an open investment offering under Regulation Crowdfunding alongside a live webinar on April 30th. The event will allow investors, supporters, and the public to see BioXgen's cardiac patch demonstrated on a heart model and hear directly from the company's leadership about its development progress, regulatory milestones, and path toward first-in-human use.

Why it matters

Each year, over 500,000 Americans undergo open-heart surgery, with nearly half developing postoperative atrial fibrillation (POAF), a common and serious complication. BioXgen's cardiac patch is designed to address this unmet need, with clinical data showing a tenfold reduction in POAF rates.

The details

BioXgen reports that its cardiac patch is fully developed and that its FDA pre-submission has been filed, marking an important step toward final regulatory review. During the webinar, the company's leadership will present the device, explain its application during surgery, discuss the clinical rationale, and answer live questions from attendees about the technology and investment opportunity.

  • BioXgen announced the open investment offering and webinar on April 16, 2026.
  • The live webinar is scheduled for April 30, 2026, at 10:30 a.m. Pacific Time.

The players

BioXgen

A medical device startup developing a cardiac patch intended to prevent postoperative atrial fibrillation, a common complication of open-heart surgery.

Dr. David Skinner

The President and CEO of BioXgen.

Dr. John Konhilas

A BioXgen executive who will present the device and discuss the clinical rationale during the webinar.

Got photos? Submit your photos here. ›

What they’re saying

“This is a chance for investors to see exactly what BioXgen has built and why we believe it could change the future of open-heart surgery.”

— Dr. David Skinner, President and CEO of BioXgen

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

BioXgen's cardiac patch represents a promising solution to a common and serious complication of open-heart surgery, with the potential to improve outcomes for hundreds of thousands of patients each year. The company's upcoming webinar and investment offering provide an opportunity for the public to learn more about this innovative technology.